SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories gains on entering into manufacturing collaboration with Tokyo-based API

13 Mar 2013 Evaluate

Neuland Laboratories is currently trading at Rs. 98.75, up by 2.75 points or 2.86% from its previous closing of Rs. 96.00 on the BSE.

The scrip opened at Rs. 97.80 and has touched a high and low of Rs. 98.75 and Rs. 97.80 respectively.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 197.95 on 07-Nov-2012 and a 52 week low of Rs. 64.10 on 03-May-2012.

The current market cap of the company is Rs. 75.00 crore.

The promoters holding in the company stood at 50.07% while Institutions and Non-Institutions held 0.79% and 49.14% respectively.

Neuland Laboratories, a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and contract manufacturing services to customers located in 85 countries, has entered into a manufacturing collaboration with Tokyo-based API Corporation (APIC), a healthcare unit of Mitsubishi Chemical Holdings Group that produces APIs, intermediates and investigational new drugs, along with fine chemicals and reagents.

Under the terms of the agreement, API Corporation is making an investment in Neuland’s facilities that will provide APIC with dedicated capacity for meeting the needs of its customers. The facilities will be operated by Neuland employees and the two companies will share oversight and management responsibilities.

Further, Neuland also intends to continue to independently expand its already-sizeable business in Japan, building on its significant customer base for both generic API manufacturing and contract manufacturing of APIs and intermediates.

Neuland Laboratories Share Price

14998.70 346.20 (2.36%)
30-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.20
Dr. Reddys Lab 1322.95
Cipla 1309.90
Zydus Lifesciences 891.65
Lupin 2303.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×